Pharmacotherapy of multiple myeloma

Bibliography

• HUSSEIN MA: Thalidomide: present and future in multiple myeloma. Expert. Rev. Anti-Cancer Ther. (2005) 5:25-31.
   PubMed Web of Science ®Google Scholar
• KYLE RA, THERNEAU TM, RAJKUMAR SV et al.: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. (2002) 346:564-569.
   PubMed Web of Science ®Google Scholar
• AVET-LOISEAU H, FACON T, DAVIET A et al.: 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. (1999) 59:4546-4550.
   PubMed Web of Science ®Google Scholar
• INTERNATIONAL MYELOMA WORKING GROUP: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. (2003) 121:749-757.
   PubMed Web of Science ®Google Scholar
• JEMAL A, MURRAY T, SAMUELS A, GHAFOOR A, WARD E, THUN MJ: Cancer statistics, 2003. CA Cancer J. Clin. (2003) 53:5-26.
   PubMed Web of Science ®Google Scholar
• RIEDEL DA, POTTERN LM: The epidemiology of multiple myeloma. Hematol. Oncol. Clin. North Am. (1992) 6:225-247.
   PubMed Web of Science ®Google Scholar
• BROWN LM, GRIDLEY G, POTTERN LM et al.: Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control. (2001) 12:117-125.
   PubMed Web of Science ®Google Scholar
• HUSSEIN MA, GEORGE R, RYBICKI L, KARAM MA: Skeletal trauma preceding the development of plasma cell dyscrasia: eight case reports and review of the literature. Med. Oncol. (2003) 20:349-354.
   PubMed Web of Science ®Google Scholar
• HUSSEIN MA: Multiple myeloma: an update of developments in targeted therapy. Expert Rev. Anti-Cancer Ther. (2005) 5:379-389.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, BARLOGIE B, BERENSON J, SINGHAL S et al.: A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. (2003) 348:2609-2617.
   PubMed Web of Science ®Google Scholar
• ADAMS J, PALOMBELLA VJ, SAUSVILLE EA et al.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. (1999) 59:2615-2622.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, RICHARDSON P, CHAUHAN D, PALOMBELLA VJ et al.: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. (2001) 61:3071-3076.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, MITSIADES C, AKIYAMA M et al.: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2003) 101:1530-1534.
   PubMed Web of Science ®Google Scholar
• PEKOL T, DANIELS JS, LABUTTI J et al.: Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab. Dispos. (2005) 33:771-777.
   PubMed Web of Science ®Google Scholar
• ORLOWSKI RZ, STINCHCOMBE TE, MITCHELL BS et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. (2002) 20:4420-4427.
   PubMed Web of Science ®Google Scholar
• RICHARDSON P, SONNEVELD P, SCHUSTER MW et al.: Bortezomib versus dexamethasone in relapsed multiple myeloma: a Phase III randomized study. J. Clin. Oncol. (2004):22 (14S):560s. Abstract.
   PubMedGoogle Scholar
• BLADE J, SAMSON D, REECE D et al.: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. (1998) 102:1115-1123.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, BARLOGIE B, BERENSON J et al.: A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. (2003) 348:2609-2617.
   PubMed Web of Science ®Google Scholar
• JAGANNATH S, BARLOGIE B, BERENSON JR et al.: Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer (2005) 103:1195-1200.
   PubMed Web of Science ®Google Scholar
• GARRETT IR, CHEN D, GUTIERREZ G et al.: Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J. Clin. Invest. (2003) 111:1771-1782.
   PubMed Web of Science ®Google Scholar
• OYAJOBI BO, MUNDY GR: Receptor activator of NF-κB ligand, macrophage inflammatory protein-1α, and the proteasome: novel therapeutic targets in myeloma. Cancer (2003) 97:813-817.
   PubMedGoogle Scholar
• ZANGARI M, ESSELTINE DL, NAJARIAN K et al.: Response to bortezomib (BOR) and bone metabolism in multiple myeloma patients. J. Clin. Oncol. (2005) 23:6536.
   Google Scholar
• BAUER KS, DIXON SC, FIGG WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. (1998) 55:1827-1834.
   PubMed Web of Science ®Google Scholar
• FRANKS ME, MACPHERSON GR, FIGG WD: Thalidomide. Lancet (2004) 363:1802-1811.
   PubMed Web of Science ®Google Scholar
• CHEN TL, VOGELSANG GB, PETTY BG et al.: Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab. Dispos. (1989) 17:402-405.
   PubMed Web of Science ®Google Scholar
• RAJE N, ANDERSON K: Thalidomide – a revival story. N. Engl. J. Med. (1999) 341:1606-1609.
   PubMed Web of Science ®Google Scholar
• PARMAN T, WILEY MJ, WELLS PG: Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med. (1999) 5:582-585.
   PubMed Web of Science ®Google Scholar
• UCHIYAMA H, BARUT BA, MOHRBACHER AF, CHAUHAN D, ANDERSON KC: Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood (1993) 82:3712-3720.
   PubMed Web of Science ®Google Scholar
• CHAUHAN D, UCHIYAMA H, AKBARALI Y et al.: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood (1996) 87:1104-1112.
   PubMed Web of Science ®Google Scholar
• HALLEK M, BERGSAGEL PL, ANDERSON KC: Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 91:3-21.
   PubMed Web of Science ®Google Scholar
• DAMIANO JS, CRESS AE, HAZLEHURST LA, SHTIL AA, DALTON WS: Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood (1999) 93:1658-1667.
   PubMed Web of Science ®Google Scholar
• GEITZ H, HANDT S, ZWINGENBERGER K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology (1996) 31:213-221.
   PubMed Web of Science ®Google Scholar
• VACCA A, RIBATTI D, PRESTA M et al.: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood (1999) 93:3064-3073.
   PubMed Web of Science ®Google Scholar
• BELLAMY WT, RICHTER L, FRUTIGER Y, GROGAN TM: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. (1999) 59:728-733.
   PubMed Web of Science ®Google Scholar
• SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 341:1565-1571.
   PubMed Web of Science ®Google Scholar
• BARLOGIE B, DESIKAN R, EDDLEMON P et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase II study of 169 patients. Blood (2001) 98:492-494.
   PubMed Web of Science ®Google Scholar
• ALEXANIAN R, DIMOPOULOS MA, DELASALLE K, BARLOGIE B: Primary dexamethasone treatment of multiple myeloma. Blood (1992) 80:887-890.
   PubMed Web of Science ®Google Scholar
• ALEXANIAN R, BARLOGIE B, DIXON D: High-dose glucocorticoid treatment of resistant myeloma. Ann. Intern. Med. (1986) 105:8-11.
   PubMed Web of Science ®Google Scholar
• WEBER D, RANKIN K, GAVINO M, DELASALLE K, ALEXANIAN R: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. (2003) 21:16-19.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, HAYMAN S, GERTZ MA et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. (2002) 20:4319-4323.
   PubMed Web of Science ®Google Scholar
• MILESHKIN L, BIAGI JJ, MITCHELL P et al.: Multicenter Phase II trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood (2003) 102:69-77.
   PubMed Web of Science ®Google Scholar
• PALUMBO A, BERTOLA A, FALCO P et al.: Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol. J. (2004) 5:318-324.
   PubMedGoogle Scholar
• ATTAL M, HAROUSSEAU JL, LEYVRAZ S et al.: Maintenance treatment with thalidomide after autologous transplantation for myeloma: first analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02). Blood (2004) 104:155a.
   Google Scholar
• TERPOS E, MIHOU D, SZYDLO R, TSIMIRIKA et al.: The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia (2005) 19(11):1969-1976.
   PubMed Web of Science ®Google Scholar
• CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNFα. J. Immunol. (1999) 163:380-386.
   PubMed Web of Science ®Google Scholar
• MULLER GW, CHEN R, HUANG SY et al.: Amino-substituted thalidomide analogs: potent inhibitors of TNFα production. Bioorg. Med. Chem. Lett. (1999) 9:1625-1630.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, SCHLOSSMAN RL, WELLER E, HIDESHIMA et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 100:3063-3067.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, HAYMAN SR, LACY MQ et al.: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 106:4050-4053.
   PubMed Web of Science ®Google Scholar
• BAZ R, LI L, KOTTKE-MARCHANT K et al.: The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin. Proc. (2005) 80:1568-1574.
   PubMed Web of Science ®Google Scholar
• DREDGE K, MARRIOTT JB, MACDONALD CD et al.: Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer (2002) 87:1166-1172.
   PubMed Web of Science ®Google Scholar
• DREDGE K, MARRIOTT JB, TODRYK SM et al.: Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased TH1-type immunity. J. Immunol. (2002) 168:4914-4919.
   PubMed Web of Science ®Google Scholar
• SCHEY SA, FIELDS P, BARTLETT JB et al.: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. (2004) 22:3269-3276.
   PubMed Web of Science ®Google Scholar
• MYELOMA TRIALISTS’ COLLABORATIVE GROUP: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J. Clin. Oncol. (1998) 16:3832-3842.
   PubMed Web of Science ®Google Scholar
• RIFKIN RM, HUSSEIN MA, GREGORY SA, MOHRBACHER A: Updated results from a randomized multicenter trial of DVd versus VAd in patients with newly diagnosed multiple myeloma. J. Clin. Oncol. (2004) 22:560s.
   PubMedGoogle Scholar
• HUSSEIN MA, WOOD L, HSI E et al.: A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer (2002) 95:2160-2168.
   PubMed Web of Science ®Google Scholar
• MASCI P, KARAM MA, PLATT L et al.: A Phase II trial of doxil, vincristine and reduced schedule dexamethasone (DVd) for patients with relapsed or refractory multiple myeloma. The American Society of Hematology 46th Annual Meeting and Exposition, San Diego, CA, USA (2004) 104:2415.
   Google Scholar
• AGRAWAL NR, SRKALOVIC G, SUP S et al.: Impact of pegylated doxorubicin (D), vincristine (V), reduced frequency dexamethasone (D) and thalidomide (T) [DVd-T] on bone marrow microvessel density (MVD) in newly diagnosed multiple myeloma (MM) patients (pts). Blood (2003) 102:378b.
   Google Scholar
• DURIE BG, JACOBSON J, BARLOGIE B, CROWLEY J: Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials. J. Clin. Oncol. (2004) 22:1857-1863.
   PubMed Web of Science ®Google Scholar
• HUSSEIN MA, KARAM MA, BRAND C et al.: Doxil (D), vincristine (V), reduced frequency dexamethasone (D) and revlimid (R) [DVd-R] a Phase I/II trial in advanced relapsed/refractory multiple myeloma (RMM) patients. Blood (2004) 104:63a-64a.
   Google Scholar
• ORLOWSKI RZ, VOORHEES PM, GARCIA RA et al.: Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood (2005) 105:3058-3065.
   PubMed Web of Science ®Google Scholar
• BROWSE NL, THOMAS ML: Source of non-lethal pulmonary emboli. Lancet (1974) 1:258-259.
   PubMedGoogle Scholar
• SRKALOVIC G, CAMERON MG, RYBICKI L, DEITCHER SR, KATTKE-MARCHANT K, HUSSEIN MA: Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer (2004) 101:558-566.
   PubMed Web of Science ®Google Scholar
• GEERTS WH, PINEO GF, HEIT JA et al.: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126:338S-400S.
   PubMed Web of Science ®Google Scholar
• PATRONO C, GARCIA RODRIGUEZ LA, LANDOLFI R, BAIGENT C: Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. (2005) 353:2373-2383.
   PubMed Web of Science ®Google Scholar
• BERGSAGEL DE: Melphalan/prednisone versus drug combinations for plasma cell myeloma. Eur. J. Haematol. Suppl. (1989) 51:117-123.
   PubMedGoogle Scholar
• BENSINGER WI, ROWLEY SD, DEMIRER T et al.: High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J. Clin. Oncol. (1996) 14:1447-1456.
   PubMed Web of Science ®Google Scholar
• MARIT G, FABERES C, PICO JL et al.: Autologous peripheral-blood progenitor-cell support following high-dose chemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma. J. Clin. Oncol. (1996) 14:1306-1313.
   PubMed Web of Science ®Google Scholar
• ATTAL M, HAROUSSEAU JL, STOPPA AM et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. (1996) 335:91.
   PubMed Web of Science ®Google Scholar
• POWLES R, RAJE N, MILAN S et al.: Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant. (1997) 20:435-443.
   PubMed Web of Science ®Google Scholar
• ALEGRE A, DIAZ-MEDIAVILLA J, SAN MIGUEL J et al.: Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyetico-GETH) and PETHEMA. Bone Marrow Transplant. (1998) 21:133-140.
   PubMed Web of Science ®Google Scholar
• BARLOGIE B, JAGANNATH S, DESIKAN KR et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 93:55-65.
   PubMed Web of Science ®Google Scholar
• SEGEREN CM, SONNEVELD P, VAN DER HOLT B et al.: Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized Phase III study. Blood (2003) 101:2144-2151.
   PubMed Web of Science ®Google Scholar
• CHILD JA, MORGAN GJ, DAVIES FE et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. (2003) 348:1875-1883.
   PubMed Web of Science ®Google Scholar
• ALEXANIAN R, DIMOPOULOS MA, HESTER J, DELASALLE K, CHAMPLIN R: Early myeloablative therapy for multiple myeloma. Blood (1994) 84:4278-4282.
   PubMed Web of Science ®Google Scholar
• VESOLE DH, CROWLEY JJ, CATCHATOURIAN R et al.: High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group Phase II trial. J. Clin. Oncol. (1999) 17:2173-2179.
   PubMed Web of Science ®Google Scholar
• BROWMAN GP, BERGSAGEL D, SICHERI D et al.: Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (1995) 13:2354-2360.
   PubMed Web of Science ®Google Scholar
• DURIE BG, JACOBSON J, BARLOGIE B, CROWLEY J: Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J. Clin. Oncol. (2004) 22(10):1857-1863.
   PubMed Web of Science ®Google Scholar
• RICCARDI A, MORA O, TINELLI C et al.: Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol. Eur. J. Cancer (2003) 39:31-37.
   PubMedGoogle Scholar
• BLADE J, VESOLE DH, GERTZ M: Transplantation for multiple myeloma: who, when, how often? Blood (2003) 102:3469-3477.
   PubMedGoogle Scholar
• HUSSEIN M: Role of high-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. Leukemia (2004) 18(4):893.
   PubMedGoogle Scholar
• CUNNINGHAM D, POWLES R, MALPAS J et al.: A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br. J. Haematol. (1998) 102:495-502.
   PubMed Web of Science ®Google Scholar
• BLADE J, SAN MIGUEL JF, FONTANILLAS M et al.: Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J. Clin. Oncol. (1996) 14:2167-2173.
   PubMed Web of Science ®Google Scholar
• BLADE J, ESTEVE J, RIVES S et al.: High-dose therapy autotransplantation/intensification versus continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant. (2000) 26:845-849.
   PubMed Web of Science ®Google Scholar
• BARLOGIE B: Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroup Trial S9321. Blood (2003) 102:42a.
   Web of Science ®Google Scholar
• BLADE J, ROSINOL L, SUREDA A et al. FOR PROGRAMA PARA EL ESTUDIO DE LA TERAPEUTICA EN HEMOPATIA MALIGNA (PETHEMA): High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood (2005) 106:3755-3759.
   PubMed Web of Science ®Google Scholar
• FERMAND JP, KATSAHIAN S, DIVINE M et al.: High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the group Myelome-Autogreffe. J. Clin. Oncol. (2005) 23(36):9227-9233.
   PubMed Web of Science ®Google Scholar
• LAHUERTA JJ, MARTINEZ-LOPEZ J, SERNA JD et al.: Remission status defined by immunofixation versus electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br. J. Haematol. (2000) 109:438-446.
   PubMed Web of Science ®Google Scholar
• ALEXANIAN R, WEBER D, GIRALT S et al.: Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. (2001) 27:1037-1043.
   PubMed Web of Science ®Google Scholar
• ATTAL M, HAROUSSEAU JL, FACON T et al.; THE INTERGROUPE FRANCOPHONE DU MYELOME: Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. (2003) 349:2495-2502.
   PubMed Web of Science ®Google Scholar
• MOREAU P, FACON T, ATTAL M et al.: Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood (2002) 99:731-735.
   PubMed Web of Science ®Google Scholar
• CAVO M, ZAMAGNI E, CELLINI C et al.: Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood (2002) 100:2272-2273.
   PubMed Web of Science ®Google Scholar
• CHEN Q, VAN DER SLUIS PC, BOULWARE D, HAZLEHURST LA, DALTON WS: The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood (2005) 106:698-705.
   PubMedGoogle Scholar
• CAVO M, ZAMAGNI E, TOSI P et al.: First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica (2004) 89:826-831.
   PubMed Web of Science ®Google Scholar
• CHANAN-KHAN A, MILLER KC, MCCARTHY P et al.: VAD-t (vincristine, adriamycin, dexamethasone and low-dose thalidomide) is an effective initial therapy with high response rates for patients with treatment naive multiple myeloma (MM). Blood (2004) 104:3463.
   PubMed Web of Science ®Google Scholar
• HASSOUN H, REICH L, KLIMEK VM et al.: Doxorubicin and dexamathasone followed by thalidomide and dexamethasone (AD-TD) as initial therapy for symptomatic patients with multiple myeloma. Blood (2004) 104:662a.
   Google Scholar
• MINNEMA MC, BREITKREUTZ I, AUWERDA JJ et al.: Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia (2004) 18:2044-2046.
   PubMed Web of Science ®Google Scholar
• PALUMBO A, BERTOLA A, MUSTO P et al.: A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) versus oral melphalan, prednisone (MP): an interim analysis. Blood (2004) 104(Pt 1):63a.
   Web of Science ®Google Scholar
• ZANGARI M, BARLOGIE B, ANAISSIE E et al.: Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. (2004) 126:715-721.
   PubMed Web of Science ®Google Scholar
• ZANGARI M, BARLOGIE B, LEE CK et al.: Protective effect of VELCADE(R) on thalidomide-associated deep vein thrombosis (DVT). Blood (2004) 104:4914.
   Google Scholar